Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis

Bimekizumab, a monoclonal antibody selectively inhibiting interleukin (IL) 17A and IL-17F, was Food and Drug Administration–approved in 2023 for the treatment of moderate-to-severe plaque psoriasis in adults. Clinical trials have demonstrated a comparable safety profile to other IL-17A antagonists, with a slightly increased risk of fungal infection and the additional warning for suicidal ideation and behavior.1-3 Post-hoc analyses of adverse events (AEs) associated with bimekizumab outside of clinical trials are scarce, with no studies to date published in the United States.